Tumor Detection Study Presented at "Frontiers in Biomagnetic Particles" Conference

MRX dipole map in mouse showing BT474 tumor signalOn June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific audience assembled for the international Frontiers in Biomagnetic Particles conference in Asheville, North Carolina. Carried out by researchers from Imagion Biosystems, the University of New Mexico, and Sandia National Laboratories, the study demonstrated the use of superparamagnetic relaxometry (SPMR) for specific detection of HER2 positive tumors in mice. The results suggest the utility of SPMR for sensitive and specific detection of cancer, and represent another successful step in the progression of Imagion Biosystems technology. Download the abstract of Dr. Vreeland’s presentation.